| High expression of TROP2 correlates with poor prognosis in pancreatic cancer D Fong, P Moser, C Krammel, JM Gostner, R Margreiter, M Mitterer, ... British journal of cancer 99 (8), 1290-1295, 2008 | 241 | 2008 |
| Distinct risk profiles of early and advanced atherosclerosis: prospective results from the Bruneck Study J Willeit, S Kiechl, F Oberhollenzer, G Rungger, G Egger, E Bonora, ... Arteriosclerosis, thrombosis, and vascular biology 20 (2), 529-537, 2000 | 215 | 2000 |
| Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab U De Giorgi, G Procopio, D Giannarelli, R Sabbatini, A Bearz, S Buti, ... Clinical Cancer Research 25 (13), 3839-3846, 2019 | 176 | 2019 |
| Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma MH Kropff, N Lang, G Bisping, N Dominé, G Innig, M Hentrich, M Mitterer, ... British journal of haematology 122 (4), 607-616, 2003 | 171 | 2003 |
| Procalcitonin‐reduced sensitivity and specificity in heavily leucopenic and immunosuppressed patients M Svaldi, J Hirber, AI Lanthaler, O Mayr, S Faes, E Peer, M Mitterer British journal of haematology 115 (1), 53-57, 2001 | 118 | 2001 |
| Mutations in DYT1 Extension of the phenotypic and mutational spectrum K Kabakci, K Hedrich, JC Leung, M Mitterer, P Vieregge, R Lencer, ... Neurology 62 (3), 395-400, 2004 | 100 | 2004 |
| Expression of 7F7‐antigen, a human adhesion molecule identical to intercellular adhesion molecule‐1 (ICAM‐1) in human carcinomas and their stromal fibroblasts W Vogetseder, H Feichtinger, TF Schulz, W Schwaeble, P Tabaczewski, ... International journal of cancer 43 (5), 768-773, 1989 | 94 | 1989 |
| Identification of a common variant in the TFR2 gene implicated in the physiological regulation of serum iron levels I Pichler, C Minelli, S Sanna, T Tanaka, C Schwienbacher, S Naitza, ... Human molecular genetics 20 (6), 1232-1240, 2011 | 91 | 2011 |
| Italian nivolumab expanded access program in nonsquamous non–small cell lung cancer patients: results in never-smokers and EGFR-mutant patients MC Garassino, AJ Gelibter, F Grossi, R Chiari, HS Parra, S Cascinu, ... Journal of Thoracic Oncology 13 (8), 1146-1155, 2018 | 85 | 2018 |
| Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease S Kiechl, A Muigg, P Santer, M Mitterer, G Egger, M Oberhollenzer, ... Circulation 99 (5), 614-619, 1999 | 78 | 1999 |
| Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme U De Giorgi, G Cartenì, D Giannarelli, U Basso, L Galli, E Cortesi, ... BJU international 123 (1), 98-105, 2019 | 77 | 2019 |
| A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients M Ladetto, S Sametti, JW Donovan, D Ferrero, M Astolfi, M Mitterer, ... Experimental Hematology 29 (2), 183-193, 2001 | 76 | 2001 |
| Humoral immune response in hematooncological patients and health care workers who received SARS-CoV-2 vaccinations MJ Mair, JM Berger, AS Berghoff, AM Starzer, G Ortmayr, HC Puhr, ... JAMA oncology 8 (1), 106-113, 2022 | 60 | 2022 |
| A web-and app-based connected care solution for COVID-19 in-and outpatient care: qualitative study and application development T Schinköthe, MR Gabri, M Mitterer, P Gouveia, V Heinemann, N Harbeck, ... JMIR public health and surveillance 6 (2), e19033, 2020 | 56 | 2020 |
| Low expression of junctional adhesion molecule A is associated with metastasis and poor survival in pancreatic cancer D Fong, G Spizzo, M Mitterer, A Seeber, M Steurer, G Gastl, I Brosch, ... Annals of surgical oncology 19, 4330-4336, 2012 | 53 | 2012 |
| Frequency of heterozygous Parkin mutations in healthy subjects: need for careful prospective follow-up examination of mutation carriers N Brüggemann, M Mitterer, AJ Lanthaler, A Djarmati, J Hagenah, ... Parkinsonism & related disorders 15 (6), 425-429, 2009 | 53 | 2009 |
| Determination of soluble CD21 as a parameter of B cell activation HP Huemer, C Larcher, WM Prodinger, AL Petzer, M Mitterer, N Falser Clinical & Experimental Immunology 93 (2), 195-199, 1993 | 49 | 1993 |
| T‐cell receptor excision circles: a novel prognostic parameter for the outcome of transplantation in multiple myeloma patients M Svaldi, AJ Lanthaler, M Dugas, P Lohse, N Pescosta, C Straka, ... British journal of haematology 122 (5), 795-801, 2003 | 47 | 2003 |
| Chronic active Epstein‐Barr virus disease in a case of persistent polyclonal B‐cell lymphocytosis M Mitterer, N Pescosta, F Fend, C Larcher, N Prang, F Schwarzmann, ... British journal of haematology 90 (3), 526-531, 1995 | 44 | 1995 |
| Identification and characterization of a novel membrane activation antigen with wide cellular distribution TF Schulz, M Mitterer, W Vogetseder, G Böck, BL Myones, MP Dierich European journal of immunology 18 (1), 7-11, 1988 | 44 | 1988 |
